Skip to content

Cogent Biosciences

US · COGT #2052 by market cap Listed 2016
26.72 -1.03 -3.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:53

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.7 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
120.67% +0.71pp
Institutions
394 -4
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund78.67%
Hedge Fund29.06%
VC/PE Fund7.99%
Public Company3.04%
Private Company0.56%
Individual/Insider0.55%
Government Pension Fund0.45%
Insurance Company0.35%
Sovereign Wealth Fund0.31%

Top holders as of 2026-09-30

FMR 15.43% · 26.85M sh
BlackRock 9.90% · 17.23M sh
Vanguard Portfolio Management, LLC 4.67% · 8.13M sh
State Street Global Advisors 4.46% · 7.77M sh
Vanguard Capital Management, LLC 4.28% · 7.45M sh
Janus Henderson Group plc 3.81% · 6.62M sh
Fairmount Funds Management LLC 3.18% · 5.54M sh
Commodore Capital LP 3.10% · 5.40M sh
Point72 Asset Management, L.P. 3.02% · 5.26M sh
Deerfield Management Company, L.P. 2.88% · 5.01M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 36 buys · 14 sells

NameRoleStake
Andrew Robbins Chief Executive Officer 0.27%
Cole Pinnow Chief Commercial Officer 0.10%
John Robinson Chief Scientific Officer 0.05%
Jessica Sachs Chief Medical Officer 0.05%
John Green Chief Financial Officer 0.05%
Evan Kearns Chief Legal Officer 0.04%
Arlene Morris Independent Director --
Matthew Ros Independent Director --
Todd Shegog Independent Director --
Karen Jean Ferrante Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-30 Karen Jean Ferrante Independent Director Other Derivative Acquisition +759 $31.59
2026-08-26 Arlene Morris Independent Director Derivative Exercise and Sale -45,510 $2.52–37.54
2026-06-30 Karen Jean Ferrante Independent Director Other Derivative Acquisition +627 $38.48
2026-06-08 Arlene Morris Independent Director Other Derivative Acquisition +17,901 $31.98
2026-06-08 Matthew Ros Independent Director Other Derivative Acquisition +17,901 $31.98
2026-06-08 Todd Shegog Independent Director Other Derivative Acquisition +17,901 $31.98
2026-06-08 Karen Jean Ferrante Independent Director Other Derivative Acquisition +17,901 $31.98
2026-06-08 Christopher Cain Independent Director Other Derivative Acquisition +17,901 $31.98
2026-06-08 Peter Harwin Independent Chairperson Other Derivative Acquisition +17,901 $31.98
2026-05-18 Andrew Robbins Chief Executive Officer Other Acquisition +160,000 --
2026-05-18 Andrew Robbins Chief Executive Officer Other Disposition -160,000 --
2026-03-31 Karen Jean Ferrante Independent Director Other Derivative Acquisition +686 $35.24
2026-03-30 Fairmount Funds Management LLC -- Derivative Exercise and Sale -7,000,000 $34.66
2026-01-21 Fairmount Funds Management LLC -- Private Disposition -3,500,000 $36.40
2025-12-31 Karen Jean Ferrante Independent Director Other Derivative Acquisition +643 $34.74
2025-12-25 John Green Chief Financial Officer Open Market Disposition -77,000 $38.68
2025-12-25 Evan Kearns Chief Legal Officer Open Market Disposition -65,000 $38.70
2025-12-25 Jessica Sachs Chief Medical Officer Open Market Disposition -82,642 $38.70
2025-12-25 John Robinson Chief Scientific Officer Open Market Disposition -90,000 $38.74
2025-12-16 Andrew Robbins Chief Executive Officer Sale to Issuer -367,497 $39.45

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:53:23 · For reference only, not investment advice and not tailored to your situation.

Cogent Biosciences discussion 0 comments

Add a comment